Inotek believes that the Company’s portfolio of proprietary poly (ADP ribose) polymerase (PARP) inhibitors have the potential to benefit patients with Age-related Macular Degeneration (AMD).
Age-related macular degeneration:
Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness in people over the age of 65, affecting 25-30 million people worldwide. There are two types of the disease – dry AMD and wet AMD. Dry AMD often progresses into wet AMD, a more advanced form of disease strongly linked to major vision loss.
The macula is the area of the eye where sharp vision occurs, allowing the eye to see fine details. In AMD, damage to the macula reduces vision in the center of the retina, creating blurriness in the center of the patient’s visual field and potentially leading to the development of a blindspot in the middle of the field of vision. The dry form of AMD is caused by the thinning of retinal tissues, breakdown of light-sensitive cells and buildup of fatty tissue behind the macula. Visual function may slowly decrease as the disease progresses. Dry AMD often transitions into wet AMD. In wet AMD, the buildup of abnormal and fragile blood vessels behind the retina leads to leakage into the retinal space, which can then physically move the macula, affecting vision dramatically and quickly.
There is no current cure for wet or dry AMD, and pharmacologic treatment options, available only for the wet form of the disease, are highly invasive. New therapeutics that address underlying pathophysiology in AMD and prevent the associated vision loss are needed.